For financial professionals in the UK

Global Life Sciences Fund

By understanding the science and business of health care, our experienced team invests in companies addressing unmet medical needs or those that seek to make the health care system more efficient.


As of 27/11/2023

1-Day Change
-0.31 (-0.60%)
As of 27/11/2023

Morningstar Rating

As of 31/10/2023


Quarterly Update

Watch the investment team recap this quarter.

(Note: Filmed in October 2023).


The Fund aims to provide capital growth over the long term.
Performance target: To outperform the MSCI World Health Care Index by at least 2% per annum, before the deduction of charges, over any 5 year period.


The Fund invests at least 80% in shares (also known as equities) of companies, of any size, with a life sciences orientation, in any country. Up to 20% may be invested in developing markets.
The Fund may also invest in other assets including cash and money market instruments.
The investment manager may use derivatives (complex financial instruments) to reduce risk, to manage the Fund more efficiently, or to generate additional capital or income for the Fund.
The Fund is actively managed with reference to the MSCI World Health Care Index, which is broadly representative of the companies in which it may invest, as this forms the basis of the Fund's performance target. The investment manager has discretion to choose individual investments for the Fund with weightings different to the index or not in the index, but at times the Fund may hold investments similar to the index.


The value of an investment and the income from it can fall as well as rise as a result of market and currency fluctuations and you may not get back the amount originally invested.
Potential investors must read the prospectus, and where relevant, the key investor information document before investing.
This website is a Marketing Communication and does not qualify as an investment recommendation.


  • Looks to invest in companies addressing unmet medical needs or those that seek to make the health care system more efficient
  • Aims to maintain a balanced portfolio across subsectors (biotechnology, health care services, medical devices and pharmaceuticals)
  • An experienced team of specialists that seeks to understand the science and the business of health care
Past performance does not predict future returns. 


Andy Acker, CFA

Portfolio Manager

Industry since 1996. Joined Firm in 1999.

Daniel Lyons, Ph.D., CFA

Portfolio Manager | Research Analyst

Industry since 2000. Joined Firm in 2000.


Past performance does not predict future returns. All performance data includes both income and capital gains or losses and reflects the deduction of any ongoing charges or other fund expenses.
Discrete Performance (%)
As of 30/09/2023
H2 GBP (Net) MSCI World Health Care NR
Quarter End
As of 30/09/2023
Sep-2022 - Sep-2023 Sep-2021 - Sep-2022 Sep-2020 - Sep-2021 Sep-2019 - Sep-2020 Sep-2018 - Sep-2019
H2 GBP (Net) 3.15 6.23 12.20 24.64 -0.51
MSCI World Health Care NR 1.41 8.96 13.73 15.16 3.89
Cumulative & Annualised Performance (%)
As of 31/10/2023
H2 GBP (Net) MSCI World Health Care NR
  Cumulative Annualised
1MO YTD 1YR 3YR 5YR 10YR Since Inception
H2 GBP (Net) -5.93 -7.78 -8.05 5.74 8.84 13.60 16.06
MSCI World Health Care NR -3.55 -6.84 -6.94 8.42 8.75 11.54 13.30
3YR 5YR 10YR Since Inception
H2 GBP (Gross) - 9.81 14.67 17.16
MSCI World Health Care NR + 2.00% - 10.92 13.77 15.57
Calendar Year Returns (%)
As of 30/09/2023
H2 GBP (Net) MSCI World Health Care NR
YTD 2022 2021 2020 2019 2018 2017 2016 2015 2014 PERFORMANCE INCEPTION
H2 GBP (Net) -1.97 8.72 7.43 21.29 24.09 9.60 11.67 4.59 13.43 43.05 48.90
MSCI World Health Care NR -3.41 6.50 20.91 10.01 18.49 8.88 9.43 11.16 12.77 25.44 31.92
Initial Charge 0.00%
Annual Charge 0.80%
Ongoing Charge
(As of 30/06/2023)


Top Holdings (As of 31/10/2023)
UnitedHealth Group Inc 7.48
Eli Lilly & Co 5.37
Novo Nordisk A/S 4.35
AstraZeneca PLC 4.11
Merck & Co Inc 3.16
Sanofi SA 2.79
AbbVie Inc 2.66
Abbott Laboratories 2.64
Vertex Pharmaceuticals Inc 2.59
Novartis AG (ADR) 2.49
Total 37.64
Sector Allocation % OF FUND % OF FUND (As of 31/10/2023)
Regional Allocation % OF FUND % OF FUND (As of October 31, 2023)


  • ​The value of the Funds and the income from them is not guaranteed and may fall as well as rise. You may get back less than you originally invested.
  • ​Past performance does not predict future returns.
  • Third party data is believed to be reliable, but its completeness and accuracy is not guaranteed.
  • Shares/Units can lose value rapidly, and typically involve higher risks than bonds or money market instruments. The value of your investment may fall as a result.
  • Shares of small and mid-size companies can be more volatile than shares of larger companies, and at times it may be difficult to value or to sell shares at desired times and prices, increasing the risk of losses.
  • If a Fund has a high exposure to a particular country or geographical region it carries a higher level of risk than a Fund which is more broadly diversified.
  • The Fund is focused towards particular industries or investment themes and may be heavily impacted by factors such as changes in government regulation, increased price competition, technological advancements and other adverse events.
  • The Fund may use derivatives to help achieve its investment objective. This can result in leverage (higher levels of debt), which can magnify an investment outcome. Gains or losses to the Fund may therefore be greater than the cost of the derivative. Derivatives also introduce other risks, in particular, that a derivative counterparty may not meet its contractual obligations.
  • If the Fund holds assets in currencies other than the base currency of the Fund, or you invest in a share/unit class of a different currency to the Fund (unless hedged, i.e. mitigated by taking an offsetting position in a related security), the value of your investment may be impacted by changes in exchange rates.
  • When the Fund, or a share/unit class, seeks to mitigate exchange rate movements of a currency relative to the base currency (hedge), the hedging strategy itself may positively or negatively impact the value of the Fund due to differences in short-term interest rates between the currencies.
  • Securities within the Fund could become hard to value or to sell at a desired time and price, especially in extreme market conditions when asset prices may be falling, increasing the risk of investment losses.
  • The Fund could lose money if a counterparty with which the Fund trades becomes unwilling or unable to meet its obligations, or as a result of failure or delay in operational processes or the failure of a third party provider.
  • Funds incur costs as a necessary part of buying and selling the underlying investments, these are otherwise known as portfolio transaction costs, and include charges such as broker commission and Stamp Duty.
  • Before investing in any of our funds you should satisfy yourself as to the suitability and the risks involved.
  • Summary of Investor rights
  • Janus Henderson Investors Europe S.A. may decide to terminate the marketing arrangements of this Collective Investment Scheme in accordance with the appropriate regulation.
  • Information on compliance with EU Sustainability related disclosures can be found here.
  • For detailed product information including the risks associated with investing please read the relevant Prospectus or Annual Report. Please refer to the prospectus of the UCITS and to the KID before making any final investment decisions.